Pay in 4 interest-free payments of $5.48 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
That's all for this issue of The Refill, a LinkedIn newsletter from Pharmacy Times
Currently, multiple phase 3 trials with oral semaglutide and orforglipron are ongoing for different populations (NCT05803421), while another oral GLP-1 RA (CT-996) is in early phase clinical trials (Table 1)
Registered dietitian Beth Czerwony of the Cleveland Clinic notes that fat-heavy foods hitting a slowed stomach is one of the most common triggers for nausea and vomiting in new GLP-1 users
The Tapering Strategy : Avoid cold turkey cessation
US$ 24.68
US$ 28.30
US$ 21.82
